Cardiovascular Risk and the Use of Biologic Agents in Rheumatoid Arthritis

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Although patients with rheumatoid arthritis (RA) are recognized to be disproportionately impacted by cardiovascular disease (CVD), effective approaches of primary and secondary CVD prevention have not been well defined in this population. Given their robust disease-modifying potential and effects on both pro-inflammatory and pro-atherogenic pathways, there has been substantial speculation that biologic treatments may serve as a means of providing highly effective RA disease control while simultaneously reducing CVD risk in this high risk group. In this review, we examine available evidence relevant to the associations of approved biologic treatments with CVD outcomes in the context of RA.

Original languageEnglish (US)
Article number459
JournalCurrent rheumatology reports
Volume16
Issue number11
DOIs
StatePublished - Jan 1 2014

Fingerprint

Biological Factors
Rheumatoid Arthritis
Cardiovascular Diseases
Therapeutics
Population

Keywords

  • Atherosclerosis
  • Biologic
  • Cardiovascular disease
  • Myocardial infarction
  • Rheumatoid arthritis
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Rheumatology

Cite this

Cardiovascular Risk and the Use of Biologic Agents in Rheumatoid Arthritis. / Lim, Debbie T.; Cannella, Amy C; Michaud, Kaleb D; Mikuls, Ted R.

In: Current rheumatology reports, Vol. 16, No. 11, 459, 01.01.2014.

Research output: Contribution to journalReview article

@article{a58f5dfce9d8484c8c0222b035532a29,
title = "Cardiovascular Risk and the Use of Biologic Agents in Rheumatoid Arthritis",
abstract = "Although patients with rheumatoid arthritis (RA) are recognized to be disproportionately impacted by cardiovascular disease (CVD), effective approaches of primary and secondary CVD prevention have not been well defined in this population. Given their robust disease-modifying potential and effects on both pro-inflammatory and pro-atherogenic pathways, there has been substantial speculation that biologic treatments may serve as a means of providing highly effective RA disease control while simultaneously reducing CVD risk in this high risk group. In this review, we examine available evidence relevant to the associations of approved biologic treatments with CVD outcomes in the context of RA.",
keywords = "Atherosclerosis, Biologic, Cardiovascular disease, Myocardial infarction, Rheumatoid arthritis, Tumor necrosis factor",
author = "Lim, {Debbie T.} and Cannella, {Amy C} and Michaud, {Kaleb D} and Mikuls, {Ted R}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11926-014-0459-y",
language = "English (US)",
volume = "16",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "11",

}

TY - JOUR

T1 - Cardiovascular Risk and the Use of Biologic Agents in Rheumatoid Arthritis

AU - Lim, Debbie T.

AU - Cannella, Amy C

AU - Michaud, Kaleb D

AU - Mikuls, Ted R

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Although patients with rheumatoid arthritis (RA) are recognized to be disproportionately impacted by cardiovascular disease (CVD), effective approaches of primary and secondary CVD prevention have not been well defined in this population. Given their robust disease-modifying potential and effects on both pro-inflammatory and pro-atherogenic pathways, there has been substantial speculation that biologic treatments may serve as a means of providing highly effective RA disease control while simultaneously reducing CVD risk in this high risk group. In this review, we examine available evidence relevant to the associations of approved biologic treatments with CVD outcomes in the context of RA.

AB - Although patients with rheumatoid arthritis (RA) are recognized to be disproportionately impacted by cardiovascular disease (CVD), effective approaches of primary and secondary CVD prevention have not been well defined in this population. Given their robust disease-modifying potential and effects on both pro-inflammatory and pro-atherogenic pathways, there has been substantial speculation that biologic treatments may serve as a means of providing highly effective RA disease control while simultaneously reducing CVD risk in this high risk group. In this review, we examine available evidence relevant to the associations of approved biologic treatments with CVD outcomes in the context of RA.

KW - Atherosclerosis

KW - Biologic

KW - Cardiovascular disease

KW - Myocardial infarction

KW - Rheumatoid arthritis

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=84920269173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920269173&partnerID=8YFLogxK

U2 - 10.1007/s11926-014-0459-y

DO - 10.1007/s11926-014-0459-y

M3 - Review article

C2 - 25315196

AN - SCOPUS:84920269173

VL - 16

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 11

M1 - 459

ER -